Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eluxadoline

FDA-approved product (tablet, oral), marketed as Eluxadoline, Viberzi.

Registered studies
10
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Eluxadoline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrheal disease
  • Irritable bowel syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antipropulsives
FDA pharmacologic class
mu-Opioid Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eluxadoline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eluxadoline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome

    NCT07635394 · start 2026-04-07

    Registered record
    Registry ID
    NCT07635394
    Conditions
    Irritable Bowel Syndrome (IBS)
    Interventions
    The pregabalin group; Routine Treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-07
    Completion
    2029-03-31
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome (IBS)
    InterventionThe pregabalin group; Routine Treatment
    PhaseNot applicable
    Registry statusRecruiting

  • Investigation of Eluxadoline for Diabetic Diarrhea

    NCT04313088 · start 2022-07-01

    Registered record
    Registry ID
    NCT04313088
    Conditions
    Diabetic Diarrhea; Diabetes; Diarrhea
    Interventions
    Eluxadoline 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2022-07-01
    Completion
    2024-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Diarrhea; Diabetes; Diarrhea
    InterventionEluxadoline 100 mg
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

    NCT04880876 · start 2021-08-13

    Registered record
    Registry ID
    NCT04880876
    Conditions
    Irritable Bowel Syndrome
    Interventions
    25mg Eluxadoline; 100mg Eluxadoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2021-08-13
    Completion
    2032-12
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    Intervention25mg Eluxadoline; 100mg Eluxadoline
    PhasePhase 3
    Registry statusEnrolling by invitation

  • Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence

    NCT03489265 · start 2019-04

    Registered record
    Registry ID
    NCT03489265
    Conditions
    Fecal Incontinence; Accidental Bowel Leakage; Anal Incontinence; Diarrhea; Urge Incontinence
    Interventions
    Eluxadoline 100 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-04
    Completion
    2020-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFecal Incontinence; Accidental Bowel Leakage; Anal Incontinence; Diarrhea +1 more
    InterventionEluxadoline 100 mg; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Eluxadoline Bile Acid Malabsorption (BAM) Study

    NCT03441581 · start 2018-02-23

    Registered record
    Registry ID
    NCT03441581
    Conditions
    Irritable Bowel Syndrome With Diarrhea
    Interventions
    Eluxadoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-23
    Completion
    2020-04-28
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome With Diarrhea
    InterventionEluxadoline
    PhasePhase 4
    Registry statusCompleted

  • Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

    NCT03339128 · start 2017-11-15

    Registered record
    Registry ID
    NCT03339128
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Eluxadoline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-15
    Completion
    2026-08-17
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionEluxadoline; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

    NCT02959983 · start 2016-10-25

    Registered record
    Registry ID
    NCT02959983
    Conditions
    Irritable Bowel Syndrome With Diarrhea
    Interventions
    Eluxadoline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10-25
    Completion
    2018-01-22
    Enrolment
    346

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome With Diarrhea
    InterventionEluxadoline; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

    NCT01553591 · start 2012-05-29

    Registered record
    Registry ID
    NCT01553591
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Eluxadoline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-29
    Completion
    2014-07-29
    Enrolment
    1,282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionEluxadoline; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

    NCT01553747 · start 2012-05-29

    Registered record
    Registry ID
    NCT01553747
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Eluxadoline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-29
    Completion
    2014-01-09
    Enrolment
    1,146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionEluxadoline; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

    NCT01130272 · start 2010-04-28

    Registered record
    Registry ID
    NCT01130272
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Eluxadoline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04-28
    Completion
    2011-07-14
    Enrolment
    807

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionEluxadoline; Placebo
    PhasePhase 2
    Registry statusCompleted